# Missouri Attorney General Issues Warning on Unsafe Cannabis Products > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/missouri-cannabis-product-safety-warning/ > **Published:** 2026-03-25T21:34:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:21-04:00 > **Clinical Summary:** Missouri cannabis product safety warning highlights risks of unlicensed, mislabeled cannabis products. Learn about the attorney general's alert and patient safety. --- ✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicySafetyIndustry Why This Matters Clinicians need to counsel patients that unlicensed cannabis products lack quality control and accurate labeling, increasing risks of unexpected potency, contaminants, or misidentified ingredients that could cause adverse effects or drug interactions. Patients purchasing from unlicensed sources may receive products with THC concentrations far exceeding their tolerance or medical needs, potentially leading to acute intoxication, anxiety, psychosis, or other serious adverse events that require emergency care. Clinicians should recommend patients only purchase cannabis from licensed, regulated dispensaries where products undergo testing and labeling verification to ensure safe dosing and ingredient transparency. Clinical Summary Missouri’s Attorney General has issued a warning regarding unlicensed dispensaries selling cannabis products that are unsafe, mislabeled, and potentially deceptive to consumers, highlighting a significant gap in regulatory enforcement within the state’s legal cannabis market. Unlicensed retailers operating outside the regulated framework pose substantial risks to patient safety through inadequate quality control, inaccurate cannabinoid labeling, and unverified product composition, which directly undermines informed prescribing and patient decision-making. This enforcement warning underscores the importance of directing patients exclusively to licensed, regulated dispensaries where products undergo mandatory testing and labeling verification. Clinicians should be aware that patients obtaining cannabis from unregulated sources may be exposed to mislabeled potency, undisclosed contaminants, or misidentified products, complicating symptom management and potentially causing unexpected adverse effects. The existence of a robust unlicensed market also suggests gaps in patient education and access to legitimate products that may drive some individuals toward non-compliant sources. Clinicians should counsel patients to verify dispensary licensure through official state regulatory databases before purchase and to be skeptical of products marketed outside licensed retail channels. Dr. Caplan’s Take “When patients come to me after purchasing from unregulated sources, I’m often dealing with products that contain nothing like what the label claims, contaminated with pesticides or heavy metals, or dosed so unpredictably that I can’t safely counsel them on use. The illicit market undercuts legitimate dispensaries, but it also undermines my ability to practice evidence-based cannabis medicine, which requires knowing exactly what my patient is actually taking.” Clinical Perspective As [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expands across states, quality control and product labeling remain significant clinical concerns, as illustrated by Missouri’s recent warning about unsafe and mislabeled products from unlicensed dispensaries. Patients may unknowingly purchase cannabis with inaccurate potency labels, undisclosed contaminants, or misrepresented cannabinoid profiles, complicating both therapeutic efficacy and safety monitoring in clinical settings. The regulatory fragmentation between licensed and unlicensed markets creates a challenging landscape where patient-reported cannabis use may not reflect actual product composition, potentially confounding symptom assessments and drug interactions. Clinicians should remain aware that patients accessing cannabis through unregulated channels face unknown quality risks and should counsel patients to verify products through licensed dispensaries with third-party testing whenever possible, while documenting the known limitations of the cannabis supply chain when counseling patients about product reliability and safety. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Missouri+attorney+general+warns+of+unsafe%2C+mislabeled+cannabis+products+%7C+ksdk.com+%40drcaplan&url=https%3A%2F%2Fwww.ksdk.com%2Farticle%2Fnews%2Flocal%2Fmarijuana%2Fmissouri-attorney-general-warns-of-unsafe-mislabeled-cannabis-products%2F63-61c957dc-6d04-4598-88a8-d4e5704dde37)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.ksdk.com%2Farticle%2Fnews%2Flocal%2Fmarijuana%2Fmissouri-attorney-general-warns-of-unsafe-mislabeled-cannabis-products%2F63-61c957dc-6d04-4598-88a8-d4e5704dde37)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Missouri+attorney+general+warns+of+unsafe%2C+mislabeled+cannabis+products+%7C+ksdk.com+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.ksdk.com%2Farticle%2Fnews%2Flocal%2Fmarijuana%2Fmissouri-attorney-general-warns-of-unsafe-mislabeled-cannabis-products%2F63-61c957dc-6d04-4598-88a8-d4e5704dde37)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.ksdk.com/article/news/local/marijuana/missouri-attorney-general-warns-of-unsafe-mislabeled-cannabis-products/63-61c957dc-6d04-4598-88a8-d4e5704dde37](https://www.ksdk.com/article/news/local/marijuana/missouri-attorney-general-warns-of-unsafe-mislabeled-cannabis-products/63-61c957dc-6d04-4598-88a8-d4e5704dde37) Further Reading Evidence WatchChildhood Adversity Linked to Nearly Doubled Odds of Heart Attack in Adulthood Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 20, 2026](https://cedclinic.com/drug-enforcement-controlled-substances-regulatory-policy-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [What's in your weed? Study finds issues with labelling, tracking cannabis](https://cedclinic.com/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis/) Explore research revealing widespread labeling and tracking issues in cannabis products, emphasizing the importance of accurate product information. [Read Study Insights](https://cedclinic.com/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis/) [Missouri lawmakers send bill banning intoxicating hemp products to governor's desk](https://cedclinic.com/missouri-intoxicating-hemp-ban/) Learn about Missouri's legislative efforts to ban intoxicating hemp products to improve consumer safety and regulatory compliance. [Learn About Legislation](https://cedclinic.com/missouri-intoxicating-hemp-ban/) [Ohio cannabis recall issued after product failed to meet testing requirements](https://cedclinic.com/cbd-gummies-ohio-practical-guide-health-conscious-users/) Review a recent cannabis recall in Ohio due to failed testing, highlighting the critical role of quality control in [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/). [See Recall Details](https://cedclinic.com/cbd-gummies-ohio-practical-guide-health-conscious-users/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).